Research and Markets has announced the addition of the "Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates" report to their offering.
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates which is listed in the "also available" below.
Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.
The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker:
- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news
Business Tracker for:
- Company updates
- Merger & acquisitions
Clinical Trial Tracker:
- Scientific Publication Tracker
- Featured ADC Profile: MEDI4276
- Featured Company Profile: NBE Therapeutics
- Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates
Information about the anti-Her2 ADC pipeline is provided in a tabular format and fully referenced.
For more information about this report visit http://www.researchandmarkets.com/research/32pftp/antiher2
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005433/en/Business Wire
Last updated on: 28/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.